



Polyfluorinated Compounds: Past, Present, and Future


| | |
|-------------------------------|---|
| Journal: | <i>Environmental Science & Technology</i> |
| Manuscript ID: | es-2011-011622.R3 |
| Manuscript Type: | Feature |
| Date Submitted by the Author: | 23-Aug-2011 |
| Complete List of Authors: | Lindstrom, Andrew; USEPA, NERL Strynar, Mark; U.S. EPA, ORD/NERL/HEASD/MDAB Libelo, E.; USEPA, OPPT |
| | |

SCHOLARONE™
Manuscripts







Perfluorocarboxylic acids
(e.g., PFOA)




Perfluorosulfonic acids
(e.g., PFOS)




Fluorotelomer alcohol
(e.g., 8:2 FTOH)




Perfluorophosphonic/phosphinic acids
(e.g., If R=OH then PFOPA
If R=C8 perfluoroalkane then 8:8 PFPi)




Perfluorosulfonamide
(e.g., FOSA)




Perfluorinated cyclo sulfonates
(e.g., PFECHS)




Perfluorosulfonamidoethanol
(e.g., N-EtFOSE)




Fluorotelomer phosphate esters
(e.g., if R= OH then 8:2 monoPAP
if R= 8:2 FTO ester then 8:2 diPAP)




Polyfluorinated ether carboxylates
(e.g., 4,8-dioxa-3H-perfluorononanoate)



Polyfluorinated polymeric unit
(e.g., 1H,1H,2H,2H-perfluorodecyl acrylate)



Polyfluorinated ether sulfonates
(e.g., Perfluoro [hexyl ethyl ether sulfonate])



Polyfluorinated Compounds: Past, Present, and Future

Andrew B. Lindstrom^{1*}, Mark J. Strynar¹, and E. Laurence Libelo²

¹ U.S. Environmental Protection Agency, National Exposure Research Laboratory
Research Triangle Park, NC 27711

² U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics
Washington, DC 20460

*Corresponding author and address: Andrew B. Lindstrom
U.S. Environmental Protection Agency
Mail Drop E205-04
Research Triangle Park, NC 27711
USA
Tel: 919-541-0551
Fax: 919-541-0905
E-mail: lindstrom.andrew@epa.gov

For submission to: *Environmental Science & Technology*

Key words: Polyfluorinated chemicals, perfluorinated compounds (PFCs), perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Interest and concern about polyfluorinated compounds (PFCs), such as perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and an increasing number of other related compounds is growing as more is learned about these ubiquitous anthropogenic substances. Many of these compounds can be toxic, and they are regularly found in the blood of animals and humans worldwide. A great deal of research has been conducted in this area, but a surprising amount remains unknown about their distribution in the environment and how people ultimately become exposed. The utility of these compounds seems to ensure their continued use in one form or another for the foreseeable future, presenting a long term challenge to scientists, industry leaders, and public health officials worldwide.

Introduction

Polyfluorinated compounds (PFCs) are useful anthropogenic chemicals that have been incorporated into a wide range of products for the past six decades. This class of compounds includes thousands of chemicals but is best known for the perfluorosulfonates (PFSAs) such as perfluorooctane sulfonate (PFOS), and the perfluorocarboxylic acids (PFCAs) which include perfluorooctanoic acid (PFOA). Their numerous uses and unique physical and chemical characteristics have made it difficult to develop an understanding of how they are distributed in the environment and how people become exposed. Concerns about these compounds have developed as many satisfy the defining characteristics of persistent organic pollutants (POPs): they are toxic, extremely resistant to degradation, bioaccumulate in food chains, and can have long half-lives in humans. After research efforts documented their presence in the environment and wildlife worldwide, and further studies verified that they are very common in human blood serum, efforts

1
2
3 56 were undertaken in the U.S. and elsewhere to limit the production and emission of some of the
4
5 57 most widely used PFCs. Recent studies have indicated that these efforts may be responsible for a
6
7 58 reduction of some PFCs in the blood of humans and animals in some locations, but other PFCs
8
9 59 have remained stable or have even increased. The diversity of the PFCs and their high production
10
11 60 volume has made it difficult to gauge global trends. An additional complication is that some
12
13 61 developing regions have taken up the production of materials that have been restricted in other
14
15 62 parts of the world, making it difficult to determine if progress is being made with regard to
16
17 63 reducing global PFC emissions. Moreover, the utility of polyfluorinated chemistry makes it highly
18
19 64 likely that commercial industries will continue to develop and use these materials for the
20
21 65 foreseeable future. This feature article will explore some of the important history in this area,
22
23 66 summarize much of our current understanding, and briefly consider what might be expected in the
24
25 67 near future. Because this is intended to be a general overview, we will highlight what has
26
27 68 motivated recent interest and what still needs to be determined.
28
29
30
31
32
33
34
35

36 70 Figure 1 summarizes the basic structures of some different types of PFCs, organized by the
37
38 71 functional group (e.g., carboxylate, sulfonate, alcohol) at one end of the molecule. *Poly*fluorinated
39
40 72 hydrocarbons have multiple sites where hydrogen has been substituted with fluorine (e.g., telomer
41
42 73 alcohols), and *per*fluorinated species have had all of the hydrogens substituted with fluorine (e.g.,
43
44 74 PFOS and PFOA). These compounds have a number of unique physical and chemical
45
46 75 characteristics imparted by the fluorinated region of the molecule, including water and oil
47
48 76 repellency, thermal stability, and surfactant properties that make them very useful for a wide range
49
50 77 of industrial and consumer-use applications [1]. For example, coating an exterior surface of a
51
52 78 textile or paper product leaves the perfluorinated tail of the molecule projecting away from the
53
54
55
56
57
58
59
60

surface. Because this part of the molecule repels both water and oil, this treatment is ideal for paper packaging, textiles, and other surfaces one wants to keep clean and dry. This chemistry is also useful for surfactants and dispersants, leading to their widespread use as leveling agents for paints, lubricants, mist suppression, and fire fighting foams. A major use of PFCAs is as an emulsifier in the production of fluoropolymers [1, 2].

Toxicity

Compounds in this class were first produced in the 1940s and 1950s, well before it became common for governmental agencies in the industrialized world to require significant testing of new materials being brought to market. As companies producing these materials continued production and diversification of their product lines, more in-depth evaluations of potential health effects were conducted. The results of many of these investigations were in the form of internal reports that were not published in the peer reviewed literature. By the early 2000s, when it became apparent that PFCs were broadly distributed in the environment [3] and almost all human blood samples collected worldwide were found to contain measureable quantities of many PFCs at the ng/mL level [4], regulatory agencies began calling for a full review of all previous research and a more thorough evaluation of toxicity began. Studies involving chronic exposure of rats and monkeys to PFOS showed decreased body weight, increased liver weight, and a steep dose-response curve for mortality [5-7]. An increase in hepatocellular adenomas and thyroid follicular cell adenomas was observed in rats exposed to high levels of PFOS in their food [8] . In rodents, PFOA has been associated with increased incidence of liver, pancreas, and testicular tumors as well as weight loss, liver enlargement, and changes in lipid metabolism [9-11]. When either PFOS or PFOA is administered to pregnant mice, there is neonatal mortality and reduced

growth for the surviving pups [12]. The carcinogenicity associated with PFOA in rodents has been found to be mediated by the peroxisome proliferator-activated receptor-alpha (PPAR- α) pathway [13], but the relevance of this mechanism in humans is a matter of scientific debate.

Using these laboratory animal studies to try to estimate potential human health effects is always difficult, but in this case it is made more difficult by the fact that the toxicokinetics of different PFCs differ considerably between animal species and even between different genders within a given species [12]. For example, the half-life of PFOA in female rats is approximately four hours, while in male rats from the same strain it is closer to six days [14]. In mice, the half-life was found to be considerably longer (17-19 days), but the effect of gender was much less pronounced [15]. In humans, data suggest that the half-lives are much longer, with PFOS and PFOA approximately 5.4 and 3.8 years (arithmetic means), respectively [16], with no difference noted between genders. While half-life has generally been observed to increase in proportion to compound chain length, this is not always true, as perfluorohexane sulfonate (PFHxS, 6 carbons) has a half-life of 8.5 years in humans [16]. This relatively long half-life in humans heightens concerns about potential health effects.

While the toxicity of PFOS and PFOA has been documented in animal studies, investigations of potential health effects in workers occupationally exposed to these compounds have generally shown inconsistent results [17]. These workers may have circulating blood levels of PFCs that are hundreds of times those of non-occupationally exposed individuals [18], but it is difficult to determine conclusive results in these studies (either positive or negative) because sample populations are small, historical exposure levels are uncertain, individuals often have had

1
2
3 125 simultaneous exposures to other compounds, and they may have preexisting conditions that
4
5 126 complicate evaluations. In one study of PFOS exposed workers, bladder cancer mortality was
6
7
8 127 elevated among individuals with at least one year of exposure, but this finding was based on an
9
10 128 incidence of only three cases [19]. In a subsequent reevaluation of this cohort, bladder cancer
11
12 129 incidence was found to be similar to that of the general U.S. population, but a 1.5 – 2.0-fold risk for
13
14 130 the most highly exposed workers could not be ruled out [20]. Compared to PFOS, more studies of
15
16 131 PFOA exposed workers have been conducted. Several studies have shown a positive association
17
18 132 between PFOA exposure and cholesterol, which could have implications for the development of
19
20 133 cardiovascular disease [18, 21-23]. PFOA has also been associated with elevated uric acid, which
21
22 134 may in turn impact hypertension and cerebrovascular disease [21, 23]. Some studies have found
23
24 135 an association between PFOA exposure and prostate cancer [24, 25], but data are sparse and do not
25
26 136 allow conclusive determinations [26]. An excellent review of this evolving area of research can be
27
28 137 found in Steenland et al. [17].
29
30
31
32
33
34 138
35
36 139 Studies involving more typical background exposures in the general population are also
37
38 140 inconsistent but suggest a number of important potential health effects. Among these are studies
39
40 141 showing an association between PFOS and PFOA and decreased sperm count [27], a negative
41
42 142 association between PFOS and PFOA with birth weight and size [28, 29], higher blood levels of
43
44 143 PFOS and PFOA being related to current thyroid disease [30], and an association between PFOA
45
46 144 and elevated cholesterol [31]. Overall these data are inconclusive and the associations do not
47
48 145 necessarily indicate causality. Steenland et al. also cover this literature in their recent review [17].
49
50
51
52 146
53
54
55 147 Considering the widespread environmental occurrence and the potential health effects, the U.S.
56
57
58
59
60

Environmental Protection Agency (EPA) has issued provisional short-term health advisories for PFOS (200 ng/L) and PFOA (400 ng/L) in drinking water, estimating that short term consumption below these levels will safeguard public health [32]. Chronic exposure guidelines are being developed by the EPA and have been published by various entities for water and food, but little has been done thus far for compounds other than PFOS and PFOA. A review of current global guidelines and regulations can be found in Zushi et al. [33].

History of Production

Among the many ways used to produce PFCs, two major synthetic routes should be discussed. In the electrochemical fluorination (ECF) process, a straight chain hydrocarbon is reacted with HF and electricity to substitute all of the hydrogen atoms with fluorine [1]. Perfluorooctane sulfonyl fluoride (POSF) has been the major target compound produced in this manner, but ECF is a relatively crude process, leading to approximately 70% straight chain POSF with the balance being a variety of branched and cyclic isomers primarily from 4 – 9 carbons in total length. POSF can then be used in a series of reactions to produce *N*-methyl and *N*-ethyl perfluorooctane sulfonamidoethanol (N-MeFOSE and N-EtFOSE, Figure 1), which historically were used to produce surface coatings for textiles and paper products [34, 35]. All compounds produced from POSF have been thought of as “PFOS equivalents” as these materials have the potential to ultimately degrade or transform to PFOS. In contrast, PFOS itself is extraordinarily stable in the environment, with no known natural mechanism of degradation. The other main process for the production of PFCs is called telomerization [1]. This involves the reaction of perfluorethylene (a taxogen, $\text{CF}_2=\text{CF}_2$) and perfluoroethyl iodide (a telogen $\text{CF}_3\text{-CF}_2\text{I}$) to produce straight chain prefluorinated iodides with chain lengths that are generally divisible by 2. These prefluorinated

1
2
3 171 iodides are then used as a feedstock to make perfluorinated carboxylic acids, fluorotelomer
4
5 172 alcohols, and fluorotelomer olefins that are almost exclusively straight chain without the branched
6
7
8 173 or cyclic materials that are characteristic of ECF synthesis. The fluorotelomer-based materials are
9
10 174 used to produce polymers, textile treatments, surfactants, and food contact packaging [36]. PFOA,
11
12 175 the eight carbon carboxylate, has been widely used as an emulsion polymerization aid in the
13
14 176 production of polytetrafluoroethylene, an inert polymer used in a wide variety of applications,
15
16 177 including nonstick coatings in kitchenware, nonreactive containers for corrosive materials,
17
18 178 insulators, lubricants, and many other uses [2].
19
20
21 179
22
23
24 180 It is also important to note that thousands of different polyfluorinated compounds have been
25
26 181 synthesized and used by industry. The polyfluoroalkyl phosphate esters (PAPs) and perfluorinated
27
28 182 phosphonic acids (PFPAs) surfactants are two other groups that have recently been gaining
29
30 183 attention [37, 38]. Both classes of compounds have multiple congeners which have been identified
31
32 184 in environmental matrices at concentrations that are similar to PFOS, PFOA, and related materials.
33
34 185 Moreover, the PAPs have been recently quantified in human blood serum samples, confirming
35
36 186 exposures through some unknown pathway(s) [39].
37
38
39 187
40
41
42
43 188 The history of PFC production is difficult to accurately portray due to the proprietary nature of this
44
45 189 information, industry responses to various forms of regulation, and changing product lines. The
46
47 190 3M Company was the major producer of POSF, starting production in 1949, with the total
48
49 191 cumulative production estimated to be approximately 96,000 t in the peak years between 1970 and
50
51 192 2002 [34]. After 3M discontinued production in 2002, other companies began production to meet
52
53 193 existing market demands, with an estimated 1,000 t per year being produced since 2002 [34]. The
54
55
56
57
58
59
60

194 fluorotelomer alcohols have been widely used in the production of polymers and surface coatings
195 with an estimated annual production in 2004 of 11,000 – 13,000 t/yr [36].

196
197 As research has demonstrated that many of the long-chain PFCs are toxic, persistent, and
198 bioaccumulative, government and regulatory bodies in some parts of the world have been working
199 toward agreements and regulations that limit the production of some of the PFCs [33]. The EPA
200 worked with 3M to bring about the voluntary discontinuation of PFOS and related compounds
201 between 2000 – 2002. Starting at the same time, a series of Significant New Use Rules (SNUR)
202 were also put in place (2000, 2002, and 2007) in the U.S. to restrict the production and use of
203 materials that contained PFOS or its various precursors. The EPA then worked with 8 leading
204 chemical companies in the 2010/15 PFOA Stewardship Program to reduce emissions and residual
205 content of PFOA and long-chain PFCs by 95% by 2010, with the long term goal to work toward
206 elimination of long-chain PFCs by 2015 [40]. In 2009, PFOS and related compounds were listed
207 under Annex B of the Stockholm Convention on Persistent Organic Pollutants, which restricts
208 manufacturing and use to a few specific applications [41]. Figure 2 is a summary of some of the
209 key events in PFC history.

210

211 **Refining Analytical Approaches**

212 In many ways research in this area has been dependent on improvements in analytical
213 instrumentation, the synthesis and availability of analytical standards, and a gradually increasing
214 sophistication in analytical approaches that have evolved over the past five decades. In 1968 D.R.
215 Taves presented evidence of two forms of fluorine in human blood, one of which was the
216 inorganic fluorine ion, and another which was closely associated with serum albumin having the

characteristics of a “large stable molecule...consistent with the presence of a fluorocarbon molecule” [42]. By 1976 Taves et al. had used NMR to tentatively identify PFOA or a related compound in concentrates from human blood serum, the source of which they speculated to be common household consumer products known to contain PFCs [43]. Early analytical methods for the measurement of organic fluorine in the blood of occupationally exposed workers started in the 1970s with a laborious and nonspecific ashing technique similar to that used by Taves et al., but soon progressed to less labor intensive (but still nonspecific) methods involving electron capture detection or microwave plasma detection [44]. These techniques had relatively high levels of detection (in the $\mu\text{g/mL}$ or ppm range) and only gave tentative identification of the target analytes, but were nonetheless adequate for the evaluation of highly exposed workers. It was only after liquid chromatography/mass spectrometry (LC/MS) instrumentation became commonly available in the mid- to late 1990’s that it became possible to measure PFCs in the low ng/mL (ppb) range, allowing for the first time the accurate evaluation of background levels of PFCs in biological and environmental matrices [45]. Early work in this area was difficult due to the relatively low concentrations found in most matrices, a lack of pure authentic standards and appropriate internal standards, a lack of standardized extraction and preparation techniques, and relatively poor quality assurance procedures [46]. A series of interlaboratory comparison studies in the early 2000s indicated relatively poor comparability between labs for complex and variable matrices like water and fish, with somewhat better performance for serum samples [47, 48]. Refinement of instrumentation and methods continued, with LC triple quadrupole mass spectrometer (LC/MS/MS) quickly becoming the standard approach used by most laboratories. As research and regulatory interest in these chemicals have increased, commercial laboratories have found a market for high purity standards and mass labeled internal standards, making it possible for more

analytical laboratories to take up this research. Better quality assurance procedures, such as the routine use of daughter ion ratios to help distinguish PFCs (such as PFOS), from commonly occurring matrix contaminants, has helped refine compound identification and accuracy considerably [49]. Another important recent development is the increasing use of standard reference materials (SRM) to develop consensus values for different compounds in differing matrices, thereby providing a way to demonstrate analytical performance in each analytical batch [50]. At present, instrumentation continues to improve, with lower cost time of flight mass spectrometers now becoming available, giving many labs the ability to conduct analyses using high resolution mass accuracy and greatly improved specificity [51].

Occurrence in the Environment

Early studies which documented the presence of PFOS and other PFCs in the blood of many species of wildlife collected from wide ranging locations around the world sparked initial interest and concern [3]. Of particular interest was the fact that PFCs were both ubiquitous in humans [4] and measureable in the blood of arctic mammals, ocean going birds, and other species only found in remote locations far from human settlement [52, 53]. It was apparent that PFCs, like other POPs, undergo a “global distillation” wherein persistent materials emitted in the temperate regions are transported to polar regions where they can accumulate in the environment far from any known sources. Polar bears, seals, and whales are well known to accumulate POPs like PCBs , PBDEs, and persistent pesticides, and these species were also found to take up PFOS and some of the long-chain PFCAs [54-56]. At the same time, other studies began documenting the occurrence of PFCs in rivers, lakes, and oceans the worldwide. The highest concentrations of PFCs have typically been documented in areas with direct industrial emissions that have impacted fresh water

263 rivers and lakes with concentrations typically ranging 1 – 1000s of ng/L [57-59]. Oceanic levels
264 are typically 3 orders of magnitude lower, with levels of PFOS and PFOA typically being in the
265 range of 10 - 100 pg/L [60].
266
267 An important environmental concern is that the long-chain PFCs can bioaccumulate as they move
268 through food webs. Compounds with a perfluoroalkyl chain length (number of carbons with
269 fluorine bonds) ≥ 8 are generally more bioaccumulative than those with ≤ 7 [61, 62]. Note that
270 while PFOA has 8 total carbons, only 7 are perfluoroalkyl carbons with one additional carboxylate
271 carbon, giving it a tendency to be less well retained in many biological matrices. Humans seem to
272 be an important exception to this observation as PFOA appears to readily accumulate in human
273 serum [63]. The functional group also has an effect on bioaccumulation, with a sulfonate being
274 more likely to be retained than a carboxylate of the same size [61, 64]. These general observations
275 form the basis for the call to restrict or eliminate the use of long-chain PFCs (i.e. those $\geq C8$) [40].
276

277 **Human Exposure**

278 The fact that virtually all people living in the industrialized world have many PFCs in their blood
279 serum in the ng/mL range [4] indicates widespread exposure, but developing an understanding
280 how people become exposed is complicated by a number of factors. One of the first important
281 considerations is the long half-life of some PFCs in humans. This slow elimination time makes it
282 difficult to determine how changes in lifestyle, diet, or other exposure-related factors influence
283 blood levels. Studies have also indicated that while age apparently has little influence on
284 circulating PFC levels, gender and ethnicity do seem to influence the accumulation of some
285 compounds [65]. This indicates that lifestyle and possibly genetic factors play a role in uptake and

1
2
3 286 retention of the PFCs. There are also clear geographical differences that have been observed,
4
5
6 287 indicating that proximity to major sources or degree of urbanization also play an important role
7
8 288 [57, 63]. But one of the biggest factors influencing human exposure is likely to be changes in
9
10 289 industrial production, which have largely come about in response to regulatory pressures to
11
12
13 290 decrease production and emission of compounds considered to be potentially hazardous. Since
14
15 291 3M terminated production of POSF in 2002, PFOS in North American blood samples has
16
17 292 decreased at a rate that is consistent with its half-life in humans, suggesting that the factors
18
19
20 293 responsible for exposure were greatly reduced or eliminated at that time [66]. It is interesting to
21
22 294 note that blood levels of PFOA also began a sharp decline in 2002, but the rate of decrease has
23
24 295 been slower than the estimated half-life. This suggests that POSF production may have been
25
26 296 related to PFOA exposure in some way, but other sources remain.
27
28
29 297
30
31
32 298 The U.S. Center for Disease Control and Prevention (CDC) conducts the National Health and
33
34 299 Nutrition Examination Survey (NHANES) on a regular basis to monitor pollutant trends in the
35
36 300 U.S. population. In a study summarizing recent NHANES data, geometric mean PFOS and PFOA
37
38 301 levels declined by 32% and 25%, respectively from 1999/2000 until 2003/2004 [67]. The most
39
40 302 recent NHANES results (2007/2008) indicate that while PFOS concentrations continue to decline,
41
42 303 other PFCs have essentially remained flat (PFOA) or have increased (PFHxS, PFNA) [65]. These
43
44 304 results suggest that deliberate efforts to reduce the production of PFOS have led to reductions in
45
46 305 human exposure (in the U.S.) but the routes of exposure and control mechanisms for other PFCs
47
48 306 remain obscure.
49
50
51
52 307
53
54
55 308 Data from other countries indicate a more complex global situation with regard to human blood
56
57
58
59
60

1
2
3 309 levels. In a study involving pooled serum samples from Norwegian men aged 40 - 50 collected
4
5 310 from 1977 until 2006, PFOS, PFOA, and perfluoroheptanoic acid (PFHpA) increased by a factor
6
7
8 311 of 9 between 1977 and the mid 1990s [68]. Between 2000 and 2006 PFOS and PFOA then
9
10 312 decreased by a factor of 2. PFHxS, perfluorononanoic acid (PFNA), perfluorodecanoic acid
11
12 313 (PFDA), and perfluoroundecanoic acid (PFUnA) also increased between 1977 and the mid 1990s,
13
14 314 but their concentrations either leveled off or continued to increase until 2006 [68]. A study in
15
16 315 Germany found relatively stable PFOS and PFOA concentrations in adult males between 1977 and
17
18 316 2004 [69], while data from China have indicated dramatically increasing level of PFOS in some
19
20 317 parts of this country, while PFOA has remained relatively low [70].
21
22
23
24 318
25
26 319 At present, a number of modeling studies have estimated that low level PFC contamination of food
27
28 320 is likely to be responsible for most nonoccupational exposures in industrialized nations. In a
29
30 321 recent review, Fromme et al. evaluated potential PFC exposures from indoor and outdoor air,
31
32 322 house dust, drinking water, and food [71]. They concluded median uptake of PFOS and PFOA
33
34 323 was on the order of 2 - 3 ng/kg/day, respectively, with food being responsible for greater than 90%
35
36 324 of this exposure. However, with the wide variety of foods consumed and the difficulty in
37
38 325 establishing sensitive analytical methods that accurately measure contaminants, there is still a
39
40 326 great deal of uncertainty about the role of food as an exposure route [72]. Fish are the most
41
42 327 thoroughly examined food item, and an increasing number of studies have begun to suggest that
43
44 328 fish from contaminated water bodies may dominate exposures to PFOS and possibly other
45
46 329 long-chain PFCAs [73, 74]. For example, in a recent study of fish taken from a contaminated
47
48 330 section of the Mississippi River, bluegill fillets were found to have median PFOS concentrations of
49
50 331 between 50 and 100 ng/g of fillet [75]. Consumption of a meal sized portion (195 g) of this fish
51
52
53
54
55
56
57
58
59
60

1
2
3 332 leads to exposures in the range of 150 – 330 ng/kg /day, which is approximately 100 times higher
4
5 333 than the daily intake predicted in the study by Fromme et al [71]. This underscores the facts that
6
7 334 fish can be a major source of intake for some people and there is still a great deal to be learned
8
9 335 about PFC contamination of food. Studies have also indicated that crops grown on contaminated
10
11 336 soils can accumulate PFCs, suggesting that this may also be a source of human exposure [76].
12
13 337 This may be a particular concern in agricultural areas that receive amendments of biosolids from
14
15 338 wastewater treatment plants, as these effluents contain PFC precursors and terminal degradants
16
17 339 [77, 78]. It is also clear that consumption of contaminated drinking water can be an important
18
19 340 route of human exposure for people living in certain areas that are impacted by industrial
20
21 341 emissions. Situations where locally contaminated drinking water resources have been linked with
22
23 342 increased blood levels have been documented in Germany [69], Japan [57], Ohio and West
24
25 343 Virginia [63], and Minnesota [79].
26
27 344
28
29
30
31
32
33
34 345 Other potential routes of human exposure include air, house dust, and direct contact with PFC
35
36 346 containing consumer use items. Many of the labile precursor materials like telomer and FOSE
37
38 347 alcohols are volatile, and studies show that they can occur in the indoor environment at pg/m^3 –
39
40 348 ng/m^3 levels [80]. Once inhaled, these materials may be metabolized by normal enzymatic
41
42 349 processes, likely leading to accumulation of the end terminal degradants *in vivo*. Studies of house
43
44 350 dust indicate that contamination in 10- 100 ng/g range is quite common [81, 82], suggesting
45
46 351 inhalation of airborne material or the hand to mouth contact (particularly for children) could
47
48 352 contribute to human exposure. Direct contact with consumer use items that have been treated with
49
50 353 PFCs or which contain residuals from a manufacturing process is another potential source of
51
52 354 human exposure [83].
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

355

356 **The Future of PFCs**

357 While most of the research and regulatory effort thus far has focused on PFOS and PFOA, it is
358 important to realize that hundreds to thousands of different polyfluorinated compounds are
359 currently in use. Moreover, new formulations are being brought to market continuously and little
360 if anything is known about the environmental disposition and toxicity of these compounds [84-86].
361 While there has been some success with voluntary controls for some PFCs [40], there is limited
362 incentive for companies to join in these voluntary agreements. In fact, considering that the
363 C8-based chemistries often have the most desirable performance characteristics, it is attractive for
364 companies that are not party to the 2010/15 PFOA Stewardship Program to increase their
365 production of long-chain materials to meet continuing international market demands. Some
366 members of the international community believe that regulations to limit PFC production are
367 unnecessary because there is little evidence of human health effects or environmental damage thus
368 far. Without strong coordinated regulatory efforts, economic factors may simply shift the
369 production of these materials to locations that place greater value on economic development than
370 long term environmental concerns.

371

372 In conclusion, it is evident that scientific and regulatory communities are only starting to
373 understand and effectively manage polyfluorinated compounds. Environmental distributions,
374 routes of human and environmental exposure, and long term ecological and human health
375 consequences are still poorly described. Limited regulatory controls have been established in
376 some nations, but their long term effectiveness on a global scale remains to be determined. The
377 extreme stability of the terminal breakdown products and the increasing trend toward an integrated

world economy makes a strong case for global research and regulation, especially as new alternatives are being introduced to the market. Environmental professionals of all types face an enormous challenge in trying to meet these pressing research needs. We are at the very beginning of a new age of environmental chemistry.

Acknowledgements

The United States Environmental Protection Agency through its Offices of Research and Development and Chemical Safety and Pollution Prevention funded and managed this effort. It has been subjected to Agency review and approved for publication but does not necessarily represent official Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

References

1. Kissa, E., *Fluorinated Surfactants and Repellents*. 2nd ed.; Marcel Dekker, Inc.: New York, 2001; Vol. 97, p 640.
2. Lehmler, H. J., Synthesis of environmentally relevant fluorinated surfactants--a review. *Chemosphere* **2005**, 58, 1471-96.
3. Giesy, J. P.; Kannan, K., Global distribution of perfluorooctane sulfonate in wildlife. *Environ Sci Technol* **2001**, 35, 1339-42.
4. Kannan, K.; Corsolini, S.; Falandysz, J.; Fillmann, G.; Kumar, K. S.; Loganathan, B. G.; Mohd, M. A.; Olivero, J.; Van Wouwe, N.; Yang, J. H.; Aldoust, K. M., Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. *Environ Sci Technol* **2004**, 38, 4489-95.

1
2
3 401 5. Goldenthal, E. I., Final report, ninety day subacute rat toxicity study on Fluorad
4
5 402 Fluorochemical FC-143, International Research and Development Corporation, Study No.
6
7 403 137-089, 3M Reference No. T-3141, November 6,1978. US EPA Administrative Record,
8
9 404 AR226-0441. **1978**.
10
11
12 405 6. Goldenthal, E. I., Final report, ninety day subacute rhesus monkey toxicity study,
13
14 406 International Research and Development Corporation, Study No. 137-090, November 10, 1978.
15
16 407 US EPA Administrative Record, AR226-0447. **1978**.
17
18
19 408 7. Seacat, A. M.; Thomford, P. J.; Hansen, K. J.; Clemen, L. A.; Eldridge, S. R.; Elcombe, C.
20
21 409 R.; Butenhoff, J. L., Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats.
22
23 410 *Toxicology* **2003**, *183*, 117-31.
24
25
26 411 8. 3M Company, 104 week dietary chronic toxicity and carcinogenicity study with
27
28 412 perfluorooctane sulfonic acid potassium salt (PFOS; T-6295) in rats. Final Report. 3M Company,
29
30 413 St. Paul, MN. January 2, 2002. US EPA Administrative Record, AR226-0956. **2002**.
31
32
33 414 9. Biegel, L. B.; Hurtt, M. E.; Frame, S. R.; O'Connor, J. C.; Cook, J. C., Mechanisms of
34
35 415 extrahepatic tumor induction by peroxisome proliferators in male CD rats. *Toxicol. Sci.* **2001**, *60*,
36
37 416 44-55.
38
39
40 417 10. Cook, J. C.; Murray, S. M.; Frame, S. R.; Hurtt, M. E., INDUCTION OF LEYDIG-CELL
41
42 418 ADENOMAS BY AMMONIUM PERFLUOROOCTANOATE - A POSSIBLE
43
44 419 ENDOCRINE-RELATED MECHANISM. *Toxicol. Appl. Pharmacol.* **1992**, *113*, (2), 209-217.
45
46
47 420 11. Sibinski, L. J. *Two year oral (diet) toxicity/carcinogenicity study of fluorochemical*
48
49 421 *FC-143 in rats. Experiment No. 0281CR0012*; 3M Company/Riker Laboratories, Inc. St Paul,
50
51 422 MN, US EPA Administrative Record, 8EHQ-1087-0394: 1987.
52
53
54 423 12. Lau, C.; Anitole, K.; Hodes, C.; Lai, D.; Pfahles-Hutchens, A.; Seed, J., Perfluoroalkyl

- 424 acids: a review of monitoring and toxicological findings. *Toxicol. Sci.* **2007**, 99, (2), 366-94.
- 425 13. USEPA Science Advisory Board *SAB Review of EPA's Draft Risk Assessment of Potential*
426 *Human Health Effects Associated with PFOA and Its Salts*; EPA-SAB-06-006; U.S.
427 Environmental Protection Agency: Washington, D.C., May 30, 2006.
- 428 14. Kemper, R. A.; Jepson, G. W., Pharmacokinetics of perfluorooctanoic acid in male and
429 female rats. *Toxicol. Sci.* **2003**, 72, 716.
- 430 15. Lau, C.; Strynar, M.; Lindstrom, A. B.; Hanson, R. G.; Thibodeaux, J. R.; Barton, H. A.,
431 Pharmacokinetic evaluation of perfluorooctanoic acid in the mouse. *Toxicologist* **2005**, 84, 252.
- 432 16. Olsen, G. W.; Burris, J. M.; Ehresman, D. J.; Froehlich, J. W.; Seacat, A. M.; Butenhoff, J.
433 L.; Zobel, L. R., Half-life of serum elimination of
434 perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired
435 fluorochemical production workers. *Environ. Health Perspect.* **2007**, 115, (9), 1298-305.
- 436 17. Steenland, K.; Fletcher, T.; Savitz, D. A., Epidemiologic Evidence on the Health Effects of
437 Perfluorooctanoic Acid (PFOA). *Environ. Health Perspect.* **2010**, 118, (8), 1100-1108.
- 438 18. Olsen, G. W.; Burris, J. M.; Burlew, M. M.; Mandel, J. H., Epidemiologic assessment of
439 worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations
440 and medical surveillance examinations. *J. Occup. Environ. Med.* **2003**, 45, 260-70.
- 441 19. Alexander, B. H.; Olsen, G. W.; Burris, J. M.; Mandel, J. H.; Mandel, J. S., Mortality of
442 employees of a perfluorooctanesulphonyl fluoride manufacturing facility. *Occup. Environ. Med.*
443 **2003**, 60, 722-9.
- 444 20. Alexander, B. H.; Olsen, G. W., Bladder Cancer in Perfluorooctanesulfonyl Fluoride
445 Manufacturing Workers. *Ann. Epidemiol.* **2007**.
- 446 21. Sakr, C. J.; Kreckmann, K. H.; Green, J. W.; Gillies, P. J.; Reynolds, J. L.; Leonard, R. C.,

1
2
3 447 Cross-Sectional Study of Lipids and Liver Enzymes Related to a Serum Biomarker of Exposure
4
5 448 (ammonium perfluorooctanoate or APFO) as Part of a General Health Survey in a Cohort of
6
7 449 Occupationally Exposed Workers. *J. Occup. Environ. Med.* **2007**, *49*, (10), 1086-1096.
8
9
10 450 22. Sakr, C. J.; Leonard, R. C.; Kreckmann, K. H.; Slade, M. D.; Cullen, M. R., Longitudinal
11
12 451 study of serum lipids and liver enzymes in workers with occupational exposure to ammonium
13
14 452 perfluorooctanoate. *J. Occup. Environ. Med.* **2007**, *49*, (8), 872-9.
15
16
17 453 23. Costa, G.; Sartori, S.; Consonni, D., Thirty years of medical surveillance in
18
19 454 perfluorooctanoic acid production workers. *J. Occup. Environ. Med.* **2009**, *51*, (3), 364-72.
20
21
22 455 24. Gilliland, F. D. a. M. J. S., Mortality among employees of a perfluorooctanoic acid
23
24 456 production plant. *J. Occup. Med.* **1993**, *35*, 950-4.
25
26
27 457 25. Lundin, J. I.; Alexander, B. H.; Olsen, G. W.; Church, T. R., Ammonium
28
29 458 Perfluorooctanoate Production and Occupational Mortality. *Epidemiology* **2009**, *20*, (6), 921-928.
30
31
32 459 26. Alexander, B. J., Mortality study of workers employed at the 3M Cottage Grove facility.
33
34 460 University of Minnesota, St.Paul, MN, US Environmental Protection Agency Docket
35
36 461 AR-226-1030-a018. **2001**.
37
38
39 462 27. Joensen, U. N.; Bossi, R.; Leffers, H.; Jensen, A. A.; Skakkebaek, N. E.; Jorgensen, N., Do
40
41 463 Perfluoroalkyl Compounds Impair Human Semen Quality? *Environ. Health Perspect.* **2009**, *117*,
42
43 464 (6), 923-927.
44
45
46 465 28. Apelberg, B. J.; Witter, F. R.; Herbstman, J. B.; Calafat, A. M.; Halden, R. U.; Needham,
47
48 466 L. L.; Goldman, L. R., Cord Serum Concentrations of Perfluorooctane Sulfonate (PFOS) and
49
50 467 Perfluorooctanoate (PFOA) in Relation to Weight and Size at Birth. *Environ. Health Perspect.*
51
52 468 **2007**, *115*, (11), 1670-1676.
53
54
55 469 29. Fei, C.; McLaughlin, J. K.; Tarone, R. E.; Olsen, J., Perfluorinated Chemicals and Fetal
56
57
58
59
60

- 1
2
3 470 Growth: A Study within the Danish National Birth Cohort. *Environ. Health Perspect.* **2007**, *115*,
4
5
6 471 (11), 1677-1682.
7
8 472 30. Melzer, D.; Rice, N.; Depledge, M. H.; Henley, W. E.; Galloway, T. S., Association
9
10 473 between Serum Perfluorooctanoic Acid (PFOA) and Thyroid Disease in the US National Health
11
12 474 and Nutrition Examination Survey. *Environ. Health Perspect.* **2010**, *118*, (5), 686-692.
13
14
15 475 31. Bao, J.; Liu, W.; Liu, L.; Jin, Y.; Dai, J.; Ran, X.; Zhang, Z.; Tsuda, S., Perfluorinated
16
17 476 Compounds in the Environment and the Blood of Residents Living near Fluorochemical Plants in
18
19 477 Fuxin, China. *Environ. Sci. Technol.* **2010**, DOI:10.1021/es102610x.
20
21
22 478 32. U.S. Environmental Protection Agency *Provisional Health Advisories for*
23
24 479 *Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS)*; Washington, DC,
25
26 480 January 8, 2009, 2009.
27
28
29 481 33. Zushi, Y.; Hogarth, J.; Masunaga, S., Progress and perspective of perfluorinated compound
30
31 482 risk assessment and management in various countries and institutes In *Clean Technologies and*
32
33 483 *Environmental Policy* 2011; pp 1-12.
34
35
36 484 34. Paul, A. G.; Jones, K. C.; Sweetman, A. J., A first global production, emission, and
37
38 485 environmental inventory for perfluorooctane sulfonate. *Environ Sci Technol* **2009**, *43*, (2), 386-92.
39
40
41 486 35. Olsen, G. W.; Huang, H. Y.; Helzlsouer, K. J.; Hansen, K. J.; Butenhoff, J. L.; Mandel, J.
42
43 487 H., Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other
44
45 488 fluorochemicals in human blood. *Environ. Health Perspect.* **2005**, *113*, 539-45.
46
47
48 489 36. E. I. du Pont de Nemours and Company, DuPont Global Strategy, Comprehensive Source
49
50 490 Reduction, Presentation to EPA, January 31, 2005, US EPA Administrative Record AR226-1914
51
52 491 **2005**.
53
54
55 492 37. Begley, T. H.; Hsu, W.; Noonan, G.; Diachenko, G., Migration of fluorochemical paper
56
57
58
59
60

- additives from food-contact paper into foods and food simulants. *Food Addit. Contam.* **2008**, *25*, (3), 384-390.
38. D'Eon, J. C.; Crozier, P. W.; Furdui, V. I.; Reiner, E. J.; Libelo, E. L.; Mabury, S. A., PERFLUORINATED PHOSPHONIC ACIDS IN CANADIAN SURFACE WATERS AND WASTEWATER TREATMENT PLANT EFFLUENT: DISCOVERY OF A NEW CLASS OF PERFLUORINATED ACIDS. *Environmental Toxicology and Chemistry* **2009**, *28*, (10), 2101-2107.
39. D'Eon, J. C.; Crozier, P. W.; Furdui, V. I.; Reiner, E. J.; Libelo, E. L.; Mabury, S. A., Observation of a Commercial Fluorinated Material, the Polyfluoroalkyl Phosphoric Acid Diesters, in Human Sera, Wastewater Treatment Plant Sludge, and Paper Fibers. *Environ. Sci. Technol.* **2009**, *43*, (12), 4589-4594.
40. USEPA 2010/15 PFOA Stewardship Program. <http://www.epa.gov/oppt/pfoa/pubs/pfoastewardship.htm> (December 20, 2006),
41. United Nations Environment Programme Report of the Conference of the Parties of the Stockholm Convention on Persistent Organic Pollutants on the work of its fourth meeting. <http://chm.pops.int/Portals/0/Repository/COP4/UNEP-POPS-COP.4-38.English.pdf>
42. Taves, D., Evidence that there are two forms of fluoride in human serum. *Nature* **1968**, *217*, (133), 1050-1051.
43. Taves, D. R.; Grey, W. S.; Brey, W. S., ORGANIC FLUORIDE IN HUMAN-PLASMA - ITS DISTRIBUTION AND PARTIAL IDENTIFICATION. *Toxicol. Appl. Pharmacol.* **1976**, *37*, (1), 120-120.
44. 3M Company, Perfluorooctane Sulfonate: Current Summary of Human Sera, Health and Toxicology Data. US EPA Administrative Record, AR226-0548 **1999**.

- 1
2
3 516 45. Hansen, K. J.; Clemen, L. A.; Ellefson, M. E.; Johnson, H. O., Compound-specific,
4
5
6 517 quantitative characterization of organic fluorochemicals in biological matrices. *Environ Sci*
7
8 518 *Technol* **2001**, 35, 766-70.
- 9
10 519 46. Martin, J. W.; Mabury, S. A.; Kannan, K.; Berger, U.; Voogt, P. D.; Field, J.; Franklin, J.;
11
12 520 Giesy, J. P.; Harner, T.; Muir, D. C. G.; Scott, B.; Kaiser, M.; Järnberg, U.; Jones, K. C.;
13
14 521 Schroeder, H.; Simcik, M.; Sottani, C.; Bavel, B. V.; Kärman, A.; Lindström, G.; Leeuwen, S. V.,
15
16 522 Analytical challenges hamper perfluoroalkyl research. *Environ Sci Technol A-Pages* **2004**, 38,
17
18 523 (11), 248A-255A.
- 19
20 524 47. van Leeuwen, S. P.; Kärman, A.; van Bavel, B.; de Boer, J.; Lindström, G., Struggle for
21
22 525 quality in determination of perfluorinated contaminants in environmental and human samples.
23
24 526 *Environ Sci Technol* **2006**, 40, (24), 7854-60.
- 25
26 527 48. Lindstrom, G.; Kärman, A.; van Bavel, B., Accuracy and precision in the determination of
27
28 528 perfluorinated chemicals in human blood verified by interlaboratory comparisons. *J. Chromatogr.*
29
30 529 *A* **2009**, 1216, (3), 394-400.
- 31
32 530 49. Benskin, J. P.; Bataineh, M.; Martin, J. W., Simultaneous characterization of
33
34 531 perfluoroalkyl carboxylate, sulfonate, and sulfonamide isomers by liquid chromatography-tandem
35
36 532 mass spectrometry. *Anal. Chem.* **2007**, 79, (17), 6455-64.
- 37
38 533 50. Keller, J. M.; Calafat, A. M.; Kato, K.; Ellefson, M. E.; Reagen, W. K.; Strynar, M.;
39
40 534 O'Connell, S.; Butt, C. M.; Mabury, S. A.; Small, J.; Muir, D. C. G.; Leigh, S. D.; Schantz, M. M.,
41
42 535 Determination of perfluorinated alkyl acid concentrations in human serum and milk standard
43
44 536 reference materials. *Anal. Bioanal. Chem.* **2010**, 397, (2), 439-451.
- 45
46 537 51. Wille, K.; Bussche, J. V.; Noppe, H.; De Wulf, E.; Van Caeter, P.; Janssen, C. R.; De
47
48 538 Brabander, H. F.; Vanhaecke, L., A validated analytical method for the determination of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 539 perfluorinated compounds in surface-, sea- and sewagewater using liquid chromatography coupled
4
5 540 to time-of-flight mass spectrometry. *Journal of Chromatography A* **2010**, *1217*, (43), 6616-6622.
6
7
8 541 52. Houde, M.; Martin, J. W.; Letcher, R. J.; Solomon, K. R.; Muir, D. C., Biological
9
10 542 monitoring of polyfluoroalkyl substances: A review. *Environ Sci Technol* **2006**, *40*, (11), 3463-73.
11
12 543 53. Butt, C. M.; Berger, U.; Bossi, R.; Tomy, G. T., Levels and trends of poly- and
13
14 544 perfluorinated compounds in the arctic environment. *Sci. Total Environ.* **2010**, *408*, (15),
15
16 545 2936-2965.
17
18
19 546 54. Smithwick, M.; Norstrom, R. J.; Mabury, S. A.; Solomon, K.; Evans, T. J.; Stirling, I.;
20
21 547 Taylor, M. K.; Muir, D. C., Temporal trends of perfluoroalkyl contaminants in polar bears (*Ursus*
22
23 548 *maritimus*) from two locations in the North American Arctic, 1972-2002. *Environ Sci Technol*
24
25 549 **2006**, *40*, 1139-43.
26
27
28 550 55. Kelly, B. C.; Ikonomou, M. G.; Blair, J. D.; Surridge, B.; Hoover, D.; Grace, R.; Gobas, F.,
29
30 551 Perfluoroalkyl Contaminants in an Arctic Marine Food Web: Trophic Magnification and Wildlife
31
32 552 Exposure. *Environ. Sci. Technol.* **2009**, *43*, (11), 4037-4043.
33
34
35 553 56. Butt, C. M.; Mabury, S. A.; Kwan, M.; Wang, X.; Muir, D. C., Spatial trends of
36
37 554 perfluoroalkyl compounds in ringed seals (*Phoca hispida*) from the Canadian Arctic. *Environ*
38
39 555 *Toxicol Chem* **2008**, *27*, (3), 542-53.
40
41
42 556 57. Saito, N.; Harada, K.; Inoue, K.; Sasaki, K.; Yoshinaga, T.; Koizumi, A.,
43
44 557 Perfluorooctanoate and perfluorooctane sulfonate concentrations in surface water in Japan. *J*
45
46 558 *Occup Health* **2004**, *46*, 49-59.
47
48
49 559 58. Skutlarek, D.; Exner, M.; Färber, H., Perfluorinated surfactants in surface and drinking
50
51 560 waters. *Environ Sci Pollut Res* **2006**, *13*, (5), 299-307.
52
53
54 561 59. Nakayama, S. F.; Strynar, M. J.; Reiner, J. L.; Delinsky, A. D.; Lindstrom, A. B.,
55
56
57
58
59
60

- 562 Determination of Perfluorinated Compounds in the Upper Mississippi River Basin. *Environ. Sci.*
563 *Technol.* **2010**, *44*, (11), 4103-4109.
- 564 60. Yamashita, N.; Kannan, K.; Taniyasu, S.; Horii, Y.; Petrick, G.; Gamo, T., A global survey
565 of perfluorinated acids in oceans. *Mar Pollut Bull* **2005**, *51*, (8-12), 658-68.
- 566 61. Conder, J. M.; Hoke, R. A.; Wolf, W. d.; Russell, M. H.; Buck, R. C., Are PFCAs
567 Bioaccumulative? A Critical Review and Comparison with Regulatory Criteria and Persistent
568 Lipophilic Compounds. *Environ. Sci. Technol.* **2008**, *42*, (4), 995-1003.
- 569 62. Martin, J. W.; Mabury, S. A.; Solomon, K. R.; Muir, D. C. G., Bioconcentration and tissue
570 distribution of perfluorinated acids in rainbow trout (*Oncorhynchus mykiss*). *Environ Toxicol*
571 *Chem* **2003**, *22*, (1), 196-204.
- 572 63. Emmett, E. A.; Shofer, F. S.; Zhang, H.; Freeman, D.; Desai, C.; Shaw, L. M., Community
573 exposure to perfluorooctanoate: relationships between serum concentrations and exposure
574 sources. *J. Occup. Environ. Med.* **2006**, *48*, (8), 759-70.
- 575 64. Martin, J. W.; Whittle, D. M.; Muir, D. C.; Mabury, S. A., Perfluoroalkyl contaminants in a
576 food web from Lake Ontario. *Environ Sci Technol* **2004**, *38*, 5379-85.
- 577 65. Kato K; Wong LY; Jia LT; Kuklenyik Z; AM., C., Trends in Exposure to Polyfluoroalkyl
578 Chemicals in the U.S. Population: 1999-2008. *Environ Sci Technol.* **2011**, DOI:
579 10.1021/es1043613.
- 580 66. Olsen, G. W.; Mair, D. C.; Reagen, W. K.; Ellefson, M. E.; Ehresman, D. J.; Butenhoff, J.
581 L.; Zobel, L. R., Preliminary evidence of a decline in perfluorooctanesulfonate (PFOS) and
582 perfluorooctanoate (PFOA) concentrations in American Red Cross blood donors. *Chemosphere*
583 **2007**, *68*, (1), 105-11.
- 584 67. Calafat, A. M.; Wong, L. Y.; Kuklenyik, Z.; Reidy, J. A.; Needham, L. L., Polyfluoroalkyl

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

585 Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination
586 Survey (NHANES) 2003-2004 and Comparisons with NHANES 1999-2000. *Environ. Health*
587 *Perspect.* **2007**, *115*, (11), 1596-1602.

588 68. Haug, L. S.; Thomsen, C.; Becher, G., Time trends and the influence of age and gender on
589 serum concentrations of perfluorinated compounds in archived human samples. *Environ Sci*
590 *Technol* **2009**, *43*, (6), 2131-6.

591 69. Wilhelm, M.; Holzer, J.; Dobler, L.; Rauchfuss, K.; Midasch, O.; Kraft, M.; Angerer, J.;
592 Wiesmuller, G., Preliminary observations on perfluorinated compounds in plasma samples
593 (1977-2004) of young German adults from an area with perfluorooctanoate-contaminated drinking
594 water. *Int. J. Hyg. Environ. Health* **2009**, *212*, (2), 142-145.

595 70. Chen, C. L.; Lu, Y. L.; Zhang, X.; Geng, J.; Wang, T. Y.; Shi, Y. J.; Hu, W. Y.; Li, J., A
596 review of spatial and temporal assessment of PFOS and PFOA contamination in China. *Chem.*
597 *Ecol.* **2009**, *25*, (3), 163-177.

598 71. Fromme, H.; Tittlemier, S. A.; Volkel, W.; Wilhelm, M.; Twardella, D., Perfluorinated
599 compounds - Exposure assessment for the general population in western countries. *Int J Hyg*
600 *Environ Health* **2009**, *212*, (3), 239-270.

601 72. Trudel, D.; Horowitz, L.; Wormuth, M.; Scheringer, M.; Cousins, I. T.; Hungerbuhler, K.,
602 Estimating consumer exposure to PFOS and PFOA (vol 28, pg 251, 2008). *Risk Anal.* **2008**, *28*,
603 (3), 807-807.

604 73. Haug, L. S.; Thomsen, C.; Brantsaeter, A. L.; Kvalem, H. E.; Haugen, M.; Becher, G.;
605 Alexander, J.; Meltzer, H. M.; Knutsen, H. K., Diet and particularly seafood are major sources of
606 perfluorinated compounds in humans. *Environ. Int.* **2010**, *36*, (7), 772-778.

- 607 74. Hölzer, J. r.; Göen, T.; Just, P.; Reupert, R.; Rauchfuss, K.; Kraft, M.; Müller, J.; Wilhelm,
608 M., Perfluorinated Compounds in Fish and Blood of Anglers at Lake Möhne, Sauerland Area,
609 Germany. *Environ. Sci. Technol.* **2011**, DOI: 10.1021/es104391z.
- 610 75. Delinsky, A. D.; Strynar, M. J.; Nakayama, S. F.; Varns, J. L.; Ye, X.; McCann, P. J.;
611 Lindstrom, A. B., Determination of ten perfluorinated compounds in bluegill sunfish (*Lepomis*
612 *macrochirus*) filets. *Environmental Research* **2009**, *109*, (8), 975-84.
- 613 76. Stahl, T.; Heyn, J.; Thiele, H.; Huther, J.; Failing, K.; Georgii, S.; Brunn, H., Carryover of
614 Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) from Soil to Plants. *Arch.*
615 *Environ. Contam. Toxicol.* **2008**.
- 616 77. Yoo, H.; Washington, J. W.; Jenkins, T. M.; Ellington, J. J., Quantitative Determination of
617 Perfluorochemicals and Fluorotelomer Alcohols in Plants from Biosolid-Amended Fields using
618 LC/MS/MS and GC/MS. *Environ. Sci. Technol.* **2011**, DOI: 10.1021/es102972m
- 619 78. Sepulvado, J. G.; Blaine, A. C.; Hundal, L. S.; Higgins, C. P., Occurrence and Fate of
620 Perfluorochemicals in Soil Following the Land Application of Municipal Biosolids. *Environ. Sci.*
621 *Technol.* **2011**, DOI: 10.1021/es103903d.
- 622 79. Minnesota Pollution Control Agency *PFCs in Minnesota's Ambient Environment: 2008*

1

2

3623 *Progress Report*; Minnesota Pollution Control Agency: St. Paul, MN, 2008.

4

5624 80. Shoeib, M.; Harner, T.; M. Webster, G.; Lee, S. C., Indoor Sources of Poly- and

6

7

8625 Perfluorinated Compounds (PFCS) in Vancouver, Canada: Implications for Human Exposure.

9

10626 *Environ. Sci. Technol.* **2011**, DOI: 10.1021/es103562v.

11

12

13627 81. Shoeib, M. H., T; Wilford, BH; Jones,KC; Zhu, J. , Perfluorinated sulfonamides in indoor

14

15628 and outdoor air and indoor and dust: occurrence, partitioning, and human exposure *Environ Sci*

16

17629 *Technol.* **2005**, 39, 6599-6606.

18

19

20630 82. Strynar, M. J.; Lindstrom, A. B., Perfluorinated compounds in house dust from Ohio and

21

22631 North Carolina, USA. *Environ Sci Technol* **2008**, 42, (10), 3751-6.

23

24

25632 83. Guo, Z.; Liu, X.; Krebs, K.; Roache, N., Perfluorocarboxylic Acid Content in 116 Articles

26

27633 of Commerce. *EPA/600/R-09/033* **2009**.

28

29

30634 84. Gordon, S. C., Toxicological evaluation of ammonium 4,8-dioxa-3H-perfluorononanoate,

31

32635 a new emulsifier to replace ammonium perfluorooctanoate in fluoropolymer manufacturing.

33

34636 *Regul. Toxicol. Pharm.* **2011**, 59, (1), 64-80.

35

36

37637 85. Ritter, S. K., FLUOROCHEMICALS GO SHORT. *Chemical & Engineering News* **2010**,

38

39638 88, (5), 12-17.

40

41

42639 86. Soler, R.; Salabert, J.; Sebastian, R. M.; Vallribera, A.; Roma, N.; Ricart, S.; Molins, E.,

43

44640 Highly hydrophobic polyfluorinated azo dyes grafted on surfaces. *Chem. Commun.* **2011**, 47, (10),

45

46641 2889-2891.

47

48642

49

50

51

52

53

54

55

56

57

58

59

60

Figure 1. Generic structures for polyfluorinated compounds*

644

645

646

647

648

649

650

651

652

653

654

655

656

657

* The n = 8 linear carbon structures are shown for many of these examples, but n = 4-14 linear and/or branched carbon units are generally possible.

Figure 2. Timeline of important events in the history of polyfluorinated compounds

661